Pfizer Inc. (PFE)
Pfizer Q2 Earnings Review: Upside At Last As CEO Prepares For Trump Policy Battle
Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth in Primary Care, Specialty Care, and Oncology, but looming patent expiries and regulatory risks persist. Management's financial discipline is improving, with cost savings, debt management, and a focus on extracting value from recent M&A deals.
Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth
PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.
Pfizer Stock Pops on Q2 Beat-and-Raise
The shares of Pfizer Inc (NYSE:PFE) were last seen up 4.9% to trade at $24.4, after the pharmaceutical giant's second-quarter results beat expectations.
Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Buy Pfizer Stock At $24?
Pfizer (NYSE: PFE) has recently reported impressive second-quarter results, with both revenue and earnings exceeding analyst expectations. The company disclosed adjusted earnings of $0.78 per share on $14.65 billion in revenue, surpassing consensus estimates of $0.58 per share and $13.56 billion.
Pfizer raises profit forecast after Q2 earnings beat estimates
Pfizer Inc (NYSE:PFE, ETR:PFE) raised its full-year profit outlook on Tuesday after posting better-than-expected second-quarter earnings, driven by strong sales of key drugs including Comirnaty and Paxlovid. The drugmaker reported adjusted earnings of $0.78 per share, beating analysts' average estimate of $0.58, according to LSEG data.
Pfizer (PFE) Surpasses Q2 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.6 per share a year ago.
Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results
Pfizer hiked its full-year adjusted profit guidance on its cost cuts and strong business performance this year. The company also reported second-quarter results that topped Wall Street's estimates for the period.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (August 2025)
Shares of Pfizer ( NYSE: PFE ) lost 6.50% over the past month, bringing the stock's year-to-date loss to 11.31%.
Pfizer: Earnings Meet Pressure (Rating Upgrade)
Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major concern for future growth. Valuation appears attractive with ratios below sector medians and Wall Street seeing significant upside, yet EPS stagnation tempers enthusiasm. Despite potential for another earnings beat, a miss could trigger a selloff, while the 7.3% dividend yield offers defensive appeal amid market uncertainty.
Should You Buy Pfizer Stock Ahead of Its Q2 Results?
Pfizer (NYSE:PFE) is set to announce its earnings on Tuesday, August 5, 2025, prior to the market opening. Analyzing Pfizer's stock performance over the previous five years after earnings announcements indicates a trend towards positive movement.
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
